AEDG raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
with the nearest-neighbor (π orbitals) hopping energy γ0 ≈ 2.8 eV and the lattice constant a ≈ 2.46 Å. The conduction and valence bands correspond to the different signs. With one pz electron per atom in this model, the valence band is fully occupied, while the conduction band is vacant. The two bands touch at the zone corners (the K point in the Brillouin zone), where there is a zero density of states but no band gap. Thus, graphene exhibits a semi-metallic (or zero-gap semiconductor) character, although this is not true for a graphene sheet rolled into a carbon nanotube due to its curvature. Two of the six Dirac points are independent, while the rest are equivalent by symmetry. Near the K-points, the energy depends linearly on the wave vector, similar to a relativistic particle. Since an elementary cell of the lattice has a basis of two atoms, the wave function has an effective 2-spinor structure. Consequently, at low energies even neglecting the true spin, electrons can be described by an equation formally equivalent to the massless Dirac equation. Hence, the electrons and holes are called Dirac fermions. This pseudo-relativistic description is restricted to the chiral limit, i.e., to vanishing rest mass M0, leading to interesting additional features:
=== Selected articles === Falk, Ronald J.; Jennette, J. Charles (1988). "Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic Glomerulonephritis". New England Journal of Medicine. 318 (25): 1651–1657. doi:10.1056/NEJM198806233182504. PMID 2453802. Falk, R. J.; Terrell, R. S.; Charles, L. A.; Jennette, J. C. (1990). "Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro". Proceedings of the National Academy of Sciences. 87 (11): 4115–4119. Bibcode:1990PNAS...87.4115F. doi:10.1073/pnas.87.11.4115. PMC 54058. PMID 2161532. Jennette, J. Charles; Falk, Ronald J.; Andrassy, Konrad; Bacon, Paul A.; Churg, Jacob; Gross, Wolfgang L.; Hagen, E. Christiaan; Hoffman, Gary S.; Hunder, Gene G.; Kallenberg, Cees G. M.; McCluskey, Robert T.; Sinico, R. Alberto; Rees, Andrew J.; Es, Leendert A. Van; Waldherr, Rüdiger; Wiik, Allan (1994). "Nomenclature of Systemic Vasculitides". Arthritis & Rheumatism. 37 (2): 187–192. doi:10.1002/art.1780370206. PMID 8129773. Jennette, J. Charles; Falk, Ronald J. (1997). "Small-Vessel Vasculitis". New England Journal of Medicine. 337 (21): 1512–1523. doi:10.1056/NEJM199711203372106. PMID 9366584. Xiao, Hong; Heeringa, Peter; Hu, Peiqi; Liu, Zhi; Zhao, Minglang; Aratani, Yasuaki; Maeda, Nobuyo; Falk, Ronald J.; Jennette, J. Charles (2002). "Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice". Journal of Clinical Investigation.
=== Design for affinity === Protein–protein interactions are involved in most biotic processes. Many of the hardest-to-treat diseases, such as Alzheimer's disease, many forms of cancer (e.g., TP53), and human immunodeficiency virus (HIV) infection involve protein–protein interactions. Thus, to treat such diseases, it is desirable to design protein or protein-like therapeutics that bind one of the partners of the interaction and, thus, disrupt the disease-causing interaction. This requires designing protein-therapeutics for affinity toward its partner. Protein–protein interactions can be designed using protein design algorithms because the principles that rule protein stability also rule protein–protein binding. Protein–protein interaction design, however, presents challenges not commonly present in protein design. One of the most important challenges is that, in general, the interfaces between proteins are more polar than protein cores, and binding involves a tradeoff between desolvation and hydrogen bond formation. To overcome this challenge, Bruce Tidor and coworkers developed a method to improve the affinity of antibodies by focusing on electrostatic contributions. They found that, for the antibodies designed in the study, reducing the desolvation costs of the residues in the interface increased the affinity of the binding pair.
Sources: en.wikipedia.org
Actress Cherylee Houston has hypermobile EDS. She uses a wheelchair and was the first full-time disabled actress on Coronation Street. Drag queen Yvie Oddly, winner of the 11th season of RuPaul's Drag Race Eric the Actor, a regular caller to The Howard Stern Show Actress and activist Jameela Jamil Writer and actress Lena Dunham Australian singer Sia Singer Halsey YouTuber and disability rights activist Annie Elainey Miss America 2020 Camille Schrier Baroque flautist, musicologist, and broadcast classical music presenter Hannah French Deaf singer/songwriter Mandy Harvey YouTuber and disability rights activist Jessica Kellgren-Fozard Singer-songwriter, author and artist Martha Marlow Pornographic actor and writer Lorelei Lee Reality show contestant Trevor Jones, dead from the vascular form of the disorder Scrunchie creator Rommy Hunt Revson, dead from a ruptured aorta Japanese voice actress and singer Tomori Kusunoki Chaz Lucius, an American former professional ice hockey player
Molybdenum (42Mo) has seven isotopes in nature, with atomic masses of 92, 94-98, and 100. All are stable except 100Mo, which undergoes double beta decay with a half-life of 7.07×1018 years (the shortest known for this mode) to 100Ru. 92Mo and 98Mo are also energetically able to decay in this manner, to zirconium and ruthenium respectively; the others are theoretically stable. There are also a total of 32 synthetic isotopes known, and at least 13 metastable nuclear isomers, ranging in atomic mass from 81 to 119. The isotopes with mass 93 or lower decay by electron capture or positron emission to niobium isotopes (or zirconium after delayed proton emission); those with mass 99 or higher by ordinary beta decay to technetium. The most stable of the former are 93Mo, recently measured to have a half-life around 4800 years, and 90Mo at 5.56 hours. The most stable of the latter is the medically important 99Mo, half-life 65.932 hours, and whose decay leads to the chief isotope of technetium. By far the most stable isomer is 93m1Mo at 6.85 hours, decaying to its ground state.
== Casualties == In total, Georgia suffered three combat fatalities (all in 2008) and at least 19 servicemen were injured in Iraq. In addition, one Georgian serviceman died in a car accident and one committed suicide, both in 2007.
Sources: en.wikipedia.org
== Elongation == Elongation of the polypeptide chain involves addition of amino acids to the carboxyl end of the growing chain. The growing protein exits the ribosome through the polypeptide exit tunnel in the large subunit. Elongation starts when the fMet-tRNA enters the P site, causing a conformational change which opens the A site for the new aminoacyl-tRNA to bind. This binding is facilitated by elongation factor-Tu (EF-Tu), a small GTPase. For fast and accurate recognition of the appropriate tRNA, the ribosome utilizes large conformational changes (conformational proofreading). Now the P site contains the beginning of the peptide chain of the protein to be encoded and the A site has the next amino acid to be added to the peptide chain. The growing polypeptide connected to the tRNA in the P site is detached from the tRNA in the P site and a peptide bond is formed between the last amino acids of the polypeptide and the amino acid still attached to the tRNA in the A site. This process, known as peptide bond formation, is catalyzed by a ribozyme (the 23S ribosomal RNA in the 50S ribosomal subunit). Now, the A site has the newly formed peptide, while the P site has an uncharged tRNA (tRNA with no amino acids). The newly formed peptide in the A site tRNA is known as dipeptide and the whole assembly is called dipeptidyl-tRNA. The tRNA in the P site minus the amino acid is known to be deacylated.
In February 2020, 7-Eleven and GCash, the mobile wallet of Alipay and Globe Telecom, teamed up for the introduction of a new payment option for physical purchases: scan-to-pay (STP) via a barcode feature in the GCash app. This enables the customers to generate their unique barcodes through the GCash app and allow the cashier to scan their barcodes to complete the transaction. In 2020, due to the effect of COVID-19 pandemic in the Philippines, the Philippine Seven Corporation (PSC) slashed the store openings to 200 from the original 400 stores planned to be opened due to financial difficulties from the growing pandemic situation. On July 11, 2021, coinciding with the 94th founding anniversary of the convenience store chain, 7-Eleven Philippines opened its 3,000th store in Meycauayan. On October 15, 2024, as part of 7-Eleven Philippines' 40th year of operations, they opened their milestone 4,000th store in Newport, Makati.
In 1930 and 1931, Cecil George Paine, a pathologist at the Royal Infirmary in Sheffield, was the first to successfully use penicillin for medical treatment. He attempted to treat sycosis (eruptions in beard follicles) with penicillin but was unsuccessful, probably because the drug did not penetrate deep enough into the skin. He cured three babies with ophthalmia neonatorum, an eye infection, and a local coal miner whose eye had become infected after an accident, but he did not publish his work.
Newsom was sworn in on January 7, 2019. Several recall attempts were launched against Newsom early in his tenure but failed to gain much traction. On February 21, 2020, a recall petition was introduced by Orrin Heatlie, a deputy sheriff in Yolo County. The petition mentioned Newsom's sanctuary state policy and said laws he endorsed favored "foreign nationals, in our country illegally"; said that California had high homelessness, high taxes, and low quality of life; and described other grievances. The California secretary of state approved it for circulation on June 10, 2020. Forcing the gubernatorial recall election required a total of 1,495,709 verified signatures. By August 2020, 55,000 signatures were submitted and verified by the secretary of state, and 890 new valid signatures were submitted by October 2020. The petition was initially given a signature deadline of November 17, 2020, but it was extended to March 17, 2021, after Judge James P. Arguelles ruled that petitioners could have more time because of the pandemic. Newsom's attendance at a party at The French Laundry in November 2020, despite his public health measures; voter anger over lockdowns, job losses, school and business closures; and a $31 billion fraud scandal at the state unemployment agency were credited for the recall's growing support.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.